{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:29:04Z","timestamp":1793730544410,"version":"4.6.1"},"reference-count":126,"publisher":"Informa UK Limited","issue":"7","funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2023,7,3]]},"DOI":"10.1080\/14737175.2023.2218549","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T14:11:55Z","timestamp":1685023915000},"page":"571-586","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":25,"title":["Decision-making and challenges within the evolving treatment algorithm in spinal muscular atrophy: a clinical perspective"],"prefix":"10.1080","volume":"23","author":[{"given":"Lakshmi","family":"Balaji","sequence":"first","affiliation":[{"name":"Department of Neurology, Sydney Children\u2019s Hospital Network, Sydney, New South Wales, Australia"},{"name":"Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health UNSW, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A","family":"Farrar","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sydney Children\u2019s Hospital Network, Sydney, New South Wales, Australia"},{"name":"Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health UNSW, Sydney, Australia"},{"name":"UNSW Kensington Campus, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene M","family":"D\u2019Silva","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sydney Children\u2019s Hospital Network, Sydney, New South Wales, Australia"},{"name":"Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health UNSW, Sydney, Australia"},{"name":"UNSW Kensington Campus, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4176-4010","authenticated-orcid":false,"given":"Didu S","family":"Kariyawasam","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sydney Children\u2019s Hospital Network, Sydney, New South Wales, Australia"},{"name":"Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health UNSW, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,6]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90460-3"},{"issue":"8","key":"e_1_3_4_3_1","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrn2670","article-title":"Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?","volume":"10","author":"Burghes AH","year":"2009","unstructured":"Burghes AH, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci. 2009;10(8):597\u2013609.","journal-title":"Nat Rev Neurosci"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/8.7.1177"},{"issue":"2","key":"e_1_3_4_5_1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter M","year":"2002","unstructured":"Feldk\u00f6tter M, Schwarzer V, Wirth R, et al. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70(2):358\u2013368.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"e_1_3_4_6_1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","article-title":"Spinal muscular atrophy: in the challenge lies a solution","volume":"44","author":"Wirth B","year":"2021","unstructured":"Wirth B. Spinal muscular atrophy: in the challenge lies a solution. Trends Neurosci. 2021;44(4):306\u2013322.","journal-title":"Trends Neurosci"},{"key":"e_1_3_4_7_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","article-title":"European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy","volume":"28","author":"Kirschner J","year":"2020","unstructured":"Kirschner J, Butoianu N, Goemans N, et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Paediatr Neurol. 2020;28:38\u201343.","journal-title":"Eur J Paediatr Neurol"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190468"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27363"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2021-0216"},{"issue":"10","key":"e_1_3_4_11_1","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1080\/03007995.2021.1947216","article-title":"Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1","volume":"37","author":"Bischof M","year":"2021","unstructured":"Bischof M, Lorenzi M, Lee J, et al. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1. Curr Med Res Opin. 2021;37(10):1719\u20131730.","journal-title":"Curr Med Res Opin"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710504"},{"key":"e_1_3_4_14_1","volume-title":"Longer-term treatment with nusinersen: results in later-onset spinal muscular atrophy from the SHINE Study (1661)","author":"Claudia A. Chiriboga, Basil T. Darras, Michelle A. Farrar","year":"2020","unstructured":"Claudia A. Chiriboga, Basil T. Darras, Michelle A. Farrar, et al. Longer-term treatment with nusinersen: results in later-onset spinal muscular atrophy from the SHINE Study (1661). Neurol.; 2020; 94 (15 Supplement) 1661."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51562"},{"issue":"11","key":"e_1_3_4_16_1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo DC","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuro Disord. 2019;29(11):842\u2013856.","journal-title":"Neuro Disord"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006502"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac252"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02065-z"},{"key":"e_1_3_4_20_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2020.11.004","article-title":"Children and young adults with spinal muscular atrophy treated with nusinersen","volume":"30","author":"Osredkar D","year":"2021","unstructured":"Osredkar D, J\u00edlkov\u00e1 M, Butenko T, et al. Children and young adults with spinal muscular atrophy treated with nusinersen. Eur J Paediatr Neurol. 2021;30:1\u20138.","journal-title":"Eur J Paediatr Neurol"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27187"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.14412"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51514"},{"issue":"8","key":"e_1_3_4_24_1","first-page":"1207","article-title":"Changes in ventilatory support requirements of Spinal Muscular Atrophy (SMA) patients post gene-based Therapies","volume":"9","author":"Panagiotou P","year":"2022","unstructured":"Panagiotou P, Kanaka-Gantenbein C, Kaditis AG. Changes in ventilatory support requirements of Spinal Muscular Atrophy (SMA) patients post gene-based Therapies. Children (Basel). 2022;9(8):1207.","journal-title":"Children (Basel)"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.15171"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000001033"},{"key":"e_1_3_4_27_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.resp.2014.03.001","article-title":"Alterations of thoraco-abdominal volumes and asynchronies in patients with spinal muscle atrophy type III","volume":"197","author":"LoMauro A","year":"2014","unstructured":"LoMauro A, Romei M, Priori R, et al. Alterations of thoraco-abdominal volumes and asynchronies in patients with spinal muscle atrophy type III. Respir Physiol Neurobiol. 2014;197:1\u20138.","journal-title":"Respir Physiol Neurobiol"},{"issue":"19","key":"e_1_3_4_28_1","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1212\/WNL.0000000000206826","article-title":"Dysphagia and lung disease in children with spinal muscular atrophy treated with disease modifying agents","volume":"100","author":"Chacko A","year":"2023","unstructured":"Chacko A, Marshall J, Taylor O, et al. Dysphagia and lung disease in children with spinal muscular atrophy treated with disease modifying agents. Neurology. 2023;100(19):914\u2013920.","journal-title":"Neurology"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007527"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26633"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26769"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190416"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-0996-0994"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323822"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14902"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00656-w"},{"issue":"1","key":"e_1_3_4_37_1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00247-018-4240-7","article-title":"Ultrasound-guided cervical puncture for nusinersen administration in adolescents","volume":"49","author":"Ortiz CB","year":"2019","unstructured":"Ortiz CB, Kukreja KU, Lotze TE, et al. Ultrasound-guided cervical puncture for nusinersen administration in adolescents. Pediatr Radiol. 2019;49(1):136\u2013140.","journal-title":"Pediatr Radiol"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00247-017-4031-6"},{"key":"e_1_3_4_39_1","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3389\/fneur.2019.01166","article-title":"Clinical Implication of dosimetry of computed tomography- and fluoroscopy-guided intrathecal therapy with nusinersen in adult patients with spinal muscular atrophy","volume":"10","author":"Kizina K","year":"2019","unstructured":"Kizina K, Stolte B, Totzeck A, et al. Clinical Implication of dosimetry of computed tomography- and fluoroscopy-guided intrathecal therapy with nusinersen in adult patients with spinal muscular atrophy. Front Neurol. 2019;10:1166.","journal-title":"Front Neurol"},{"issue":"3","key":"e_1_3_4_40_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CND.0000000000000333","article-title":"Delivery of nusinersen through an ommaya reservoir in spinal muscular atrophy","volume":"22","author":"Iannaccone ST","year":"2021","unstructured":"Iannaccone ST, Paul D, Castro D, et al. Delivery of nusinersen through an ommaya reservoir in spinal muscular atrophy. J Clin Neuromuscul Dis. 2021;22(3):129\u2013134.","journal-title":"J Clin Neuromuscul Dis"},{"key":"e_1_3_4_41_1","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1016\/j.nmd.2017.06.412","article-title":"AVXS-101 phase 1 gene therapy clinical trial in SMA type 1: end-of-study event free survival and achievement of developmental milestones","volume":"27","author":"Mendell J","year":"2017","unstructured":"Mendell J, Al-Zaidy S, Shell R, et al. AVXS-101 phase 1 gene therapy clinical trial in SMA type 1: end-of-study event free survival and achievement of developmental milestones. J Neuromuscular Disorders. 2017;27:S208.","journal-title":"J Neuromuscular Disorders"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198"},{"key":"e_1_3_4_43_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of age and motor function in a phase 1\/2a study of infants with SMA type 1 receiving single-dose gene replacement therapy","volume":"98","author":"Lowes LP","year":"2019","unstructured":"Lowes LP, Alfano LN, Arnold WD, et al. Impact of age and motor function in a phase 1\/2a study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr Neurol. 2019;98:39\u201345.","journal-title":"Pediatr Neurol"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.1272"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00001-6"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00251-9"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01867-3"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01866-4"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51519"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.001"},{"key":"e_1_3_4_51_1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1","volume":"225","author":"Feldman AG","year":"2020","unstructured":"Feldman AG, Parsons JA, Dutmer CM, et al. Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1. J Pediatr. 2020;225:252\u20138.e1.","journal-title":"J Pediatr"},{"key":"e_1_3_4_52_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand DH","year":"2021","unstructured":"Chand DH, Zaidman C, Arya K, et al. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Paediatr. 2021;231:265\u2013268.","journal-title":"J Paediatr"},{"key":"e_1_3_4_53_1","volume-title":"Zolgensma acute liver failure update","author":"Novartis","year":"2022","unstructured":"Novartis. Zolgensma acute liver failure update. 2022. https:\/\/www.novartis.com\/news\/zolgensma-acute-liver-failure-update."},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102047"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15499"},{"key":"e_1_3_4_56_1","volume-title":"Annual Spinal Muscular Atrophy Research and Clinical Care Meeting","author":"Finkel RS","year":"2022","unstructured":"Finkel RS, Farrar MA, Vlodavets D , et al., editors. Rainbowfish: preliminary efficacy and safety data in Risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA). Anaheim, California: Annual Spinal Muscular Atrophy Research and Clinical Care Meeting; 2022."},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51560"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-021-00827-3"},{"key":"e_1_3_4_59_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2021.01.012","article-title":"Clinical experience with gene therapy in older patients with spinal muscular atrophy","volume":"118","author":"Matesanz SE","year":"2021","unstructured":"Matesanz SE, Battista V, Flickinger J, et al. Clinical experience with gene therapy in older patients with spinal muscular atrophy. Pediatr Neurol. 2021;118:1\u20135.","journal-title":"Pediatr Neurol"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27034"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008207"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10235540"},{"issue":"2","key":"e_1_3_4_63_1","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1002\/mus.27648","article-title":"Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec-xioi in a premature neonate with type 1 spinal muscular atrophy","volume":"66","author":"Ferrante L","year":"2022","unstructured":"Ferrante L, Melendez-Zaidi A, Lindsey W, et al. Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec-xioi in a premature neonate with type 1 spinal muscular atrophy. Muscle Nerve. 2022;66(2):E8\u2013e10.","journal-title":"Muscle Nerve"},{"issue":"3","key":"e_1_3_4_64_1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/brainsci11030367","article-title":"Nusinersen wearing-off in adult 5q-spinal muscular atrophy patients","volume":"11","author":"Osmanovic A","year":"2021","unstructured":"Osmanovic A, Schreiber-Katz O, Petri S. Nusinersen wearing-off in adult 5q-spinal muscular atrophy patients. Brain Sci. 2021;11(3):367.","journal-title":"Brain Sci"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12542"},{"issue":"7","key":"e_1_3_4_66_1","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/brain\/awac125","article-title":"Pre-symptomatic spinal muscular atrophy: a proposed nosology","volume":"145","author":"Finkel RS","year":"2022","unstructured":"Finkel RS, Benatar M. Pre-symptomatic spinal muscular atrophy: a proposed nosology. Brain. 2022;145(7):2247\u20132249.","journal-title":"Brain"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad061"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(22)00342-X"},{"issue":"1","key":"e_1_3_4_69_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JND-190424","article-title":"Advances in treatment of spinal muscular atrophy \u2013 new phenotypes, new challenges, new implications for care","volume":"7","author":"Schorling DC","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy \u2013 new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1\u201313.","journal-title":"J Neuromuscul Dis"},{"key":"e_1_3_4_70_1","doi-asserted-by":"crossref","first-page":"104851","DOI":"10.1016\/j.earlhumdev.2019.104851","article-title":"Treating neonatal spinal muscular atrophy: a 21st century success story?","volume":"138","author":"Tizzano EF","year":"2019","unstructured":"Tizzano EF. Treating neonatal spinal muscular atrophy: a 21st century success story? Early Hum Dev. 2019;138:104851.","journal-title":"Early Hum Dev"},{"issue":"10","key":"e_1_3_4_71_1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","article-title":"Spinal muscular atrophy: a changing phenotype beyond the clinical trials","volume":"27","author":"Tizzano EF","year":"2017","unstructured":"Tizzano EF, Finkel RS. Spinal muscular atrophy: a changing phenotype beyond the clinical trials. Neuromuscular Disorders. 2017;27(10):883\u2013889.","journal-title":"Neuromuscular Disorders"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.15117"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01783-8"},{"key":"e_1_3_4_74_1","first-page":"jmg-2022","article-title":"Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis","author":"Abiusi E","year":"2022","unstructured":"Abiusi E, Vaisfeld A, Fiori S, et al. Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis. J Med Genet. 2022;jmg-2022\u2013108873.","journal-title":"J Med Genet"},{"issue":"8","key":"e_1_3_4_75_1","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1172\/JCI121658","article-title":"Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain","volume":"128","author":"Sumner CJ","year":"2018","unstructured":"Sumner CJ, Crawford TO. Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain. J Clin Invest. 2018;128(8):3219\u20133227.","journal-title":"J Clin Invest"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb6871"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1113\/JP282249"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-020-00624-2"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000001179"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.25795"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.005"},{"key":"e_1_3_4_82_1","first-page":"11","article-title":"Changing respiratory expectations with the new disease trajectory of nusinersen treated spinal muscular atrophy [SMA] type 1","volume":"28","author":"Fitzgerald DA","year":"2018","unstructured":"Fitzgerald DA, Doumit M, Abel F. Changing respiratory expectations with the new disease trajectory of nusinersen treated spinal muscular atrophy [SMA] type 1. Paediatr Respir Rev. 2018;28:11\u201317.","journal-title":"Paediatr Respir Rev"},{"issue":"5","key":"e_1_3_4_83_1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: controversies and challenges","volume":"11","author":"Mercuri E","year":"2012","unstructured":"Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11(5):443\u2013452.","journal-title":"Lancet Neurol"},{"issue":"1","key":"e_1_3_4_84_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JND-190424","article-title":"Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care","volume":"7","author":"Schorling DC","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1\u201313.","journal-title":"J Neuromuscul Dis"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d3e308"},{"issue":"20","key":"e_1_3_4_86_1","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1212\/WNL.0b013e3182749eca","article-title":"Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3","volume":"79","author":"Wadman RI","year":"2012","unstructured":"Wadman RI, Vrancken AF, van den Berg LH, et al. Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology. 2012;79(20):2050\u20132055.","journal-title":"Neurology"},{"issue":"1","key":"e_1_3_4_87_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-180342","article-title":"Perceived fatigue in spinal muscular atrophy: a pilot study","volume":"6","author":"Dunaway Young S","year":"2019","unstructured":"Dunaway Young S, Montes J, Kramer SS, et al. Perceived fatigue in spinal muscular atrophy: a pilot study. J Neuromuscul Dis. 2019;6(1):109\u2013117.","journal-title":"J Neuromuscul Dis"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-1339-3"},{"issue":"1","key":"e_1_3_4_89_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13023-019-1052-2","article-title":"\u201cGetting ready for the adult world\u201d: how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being","volume":"14","author":"Wan HWY","year":"2019","unstructured":"Wan HWY, Carey KA, D\u2019Silva A, et al. \u201cGetting ready for the adult world\u201d: how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being. Orphanet J Rare Dis. 2019;14(1):74.","journal-title":"Orphanet J Rare Dis"},{"key":"e_1_3_4_90_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2020.01.003","article-title":"Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease","volume":"109","author":"Yeo CJJ","year":"2020","unstructured":"Yeo CJJ, Darras BT. Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease. Pediatr Neurol. 2020;109:12\u201319.","journal-title":"Pediatr Neurol"},{"issue":"3","key":"e_1_3_4_91_1","first-page":"175","article-title":"Cardiac involvement in patients with spinal muscular atrophies","volume":"30","author":"Palladino A","year":"2011","unstructured":"Palladino A, Passamano L, Taglia A, et al. Cardiac involvement in patients with spinal muscular atrophies. Acta Myol. 2011;30(3):175\u2013178.","journal-title":"Acta Myol"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213680"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200551"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2019-318120"},{"key":"e_1_3_4_95_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.brainres.2018.02.022","article-title":"Spinal muscular atrophy: selective motor neuron loss and global defect in the assembly of ribonucleoproteins","volume":"1693","author":"Beattie CE","year":"2018","unstructured":"Beattie CE, Kolb SJ. Spinal muscular atrophy: selective motor neuron loss and global defect in the assembly of ribonucleoproteins. Brain Res. 2018;1693(Pt A):92\u201397.","journal-title":"Brain Res"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-324254"},{"issue":"4","key":"e_1_3_4_97_1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/GRF.0000000000000654","article-title":"Spinal muscular atrophy: a potential target for in utero therapy","volume":"64","author":"Baptiste C","year":"2021","unstructured":"Baptiste C, De Vivo DC. Spinal muscular atrophy: a potential target for in utero therapy. Clin Obstet Gynecol. 2021;64(4):917\u2013925.","journal-title":"Clin Obstet Gynecol"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2009.08.002"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.01.003"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180304"},{"issue":"3","key":"e_1_3_4_101_1","first-page":"239","article-title":"Association of copy number of SMN1 and SMN2 with clinical phenotypes in children with spinal muscular atrophy","volume":"21","author":"Zhang YH","year":"2019","unstructured":"Zhang YH, Zhang YQ, Zhu BS, et al. Association of copy number of SMN1 and SMN2 with clinical phenotypes in children with spinal muscular atrophy. Zhongguo Dang Dai Er Ke Za Zhi. 2019;21(3):239\u2013243.","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20473"},{"issue":"43","key":"e_1_3_4_103_1","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.2174\/1381612825666191210154535","article-title":"Neurofilament proteins as prognostic biomarkers in neurological disorders","volume":"25","author":"Lee Y","year":"2020","unstructured":"Lee Y, Lee BH, Yip W, et al. Neurofilament proteins as prognostic biomarkers in neurological disorders. CPD. 2020;25(43):4560\u20134569.","journal-title":"CPD"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.779"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.779"},{"key":"e_1_3_4_106_1","volume-title":"Plasma Phosphorylated Neurofilament Heavy Chain (pNF-H) Level is Associated with Future Motor Function in Nusinersen-treated Individuals with later-onset Spinal Muscular Atrophy (SMA) (2248)","author":"Farrar MA, Muntoni F, Sumner CJ","year":"2021","unstructured":"Farrar MA, Muntoni F, Sumner CJ, et al. Plasma Phosphorylated Neurofilament Heavy Chain (pNF-H) Level is Associated with Future Motor Function in Nusinersen-treated Individuals with later-onset Spinal Muscular Atrophy (SMA) (2248). Neurology Apr; 2021, 96(15 Supplement) 2248 Neurology Apr 2021, 96 (15 Supplement) 2248"},{"issue":"17","key":"e_1_3_4_107_1","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.1111\/jcmm.16802","article-title":"Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen","volume":"25","author":"Johannsen J","year":"2021","unstructured":"Johannsen J, Weiss D, Daubmann A, et al. Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen. J Cell Mol Med. 2021;25(17):8419\u20138431.","journal-title":"J Cell Mol Med"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210735"},{"key":"e_1_3_4_109_1","volume-title":"Late braking abstract presented at World Muscle Society Congress 2022, Halifax, Canada, Oct","author":"Finkel R, Hughers S, Parker J","year":"2022","unstructured":"Fetal therapy for spinal muscular atrophy: a case report. Finkel R, Hughers S, Parker J, et al. Late braking abstract presented at World Muscle Society Congress 2022, Halifax, Canada, Oct 2022. WMS Full program, page 32 https:\/\/archive.worldmusclesociety.org\/www.wms2022.com\/file\/ff5d5295-702a-40ef-b575-f167017fea05\/WMS2022%20Congress%20Programme%20Full%20(25).pdf"},{"key":"e_1_3_4_110_1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.omtm.2021.10.011","article-title":"Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: a case series","volume":"23","author":"Alves CRR","year":"2021","unstructured":"Alves CRR, Petrillo M, Spellman R, et al. Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: a case series. Mol Ther - Methods Clin Dev. 2021;23:524\u2013538.","journal-title":"Mol Ther - Methods Clin Dev"},{"issue":"1","key":"e_1_3_4_111_1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/pharmaceutics15010170","article-title":"Identification of Novel CSF-Derived miRnas in treated paediatric onset spinal muscular atrophy: an exploratory study","volume":"15","author":"D\u2019Silva AM","year":"2023","unstructured":"D\u2019Silva AM, Kariyawasam D, Venkat P, et al. Identification of Novel CSF-Derived miRnas in treated paediatric onset spinal muscular atrophy: an exploratory study. Pharmaceutics. 2023;15(1):170.","journal-title":"Pharmaceutics"},{"issue":"3","key":"e_1_3_4_112_1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbagrm.2016.12.008","article-title":"Diverse role of survival motor neuron protein","volume":"1860","author":"Singh RN","year":"2017","unstructured":"Singh RN, Howell MD, Ottesen EW, et al. Diverse role of survival motor neuron protein. Biochim Biophys Acta, Gene Regul Mech. 2017;1860(3):299\u2013315.","journal-title":"Biochim Biophys Acta, Gene Regul Mech"},{"key":"e_1_3_4_113_1","doi-asserted-by":"crossref","first-page":"117727192110356","DOI":"10.1177\/11772719211035643","article-title":"Update on biomarkers in spinal muscular atrophy","volume":"16","author":"Pino MG","year":"2021","unstructured":"Pino MG, Rich KA, Kolb SJ. Update on biomarkers in spinal muscular atrophy. Biomark Insights. 2021;16:11772719211035643.","journal-title":"Biomark Insights"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203398"},{"key":"e_1_3_4_115_1","volume-title":"Update from SUNFISH Part 1: Safety, Tolerability and PK\/PD from the Dose-Finding Study, Including Exploratory Efficacy Data in Patients with Type 2 or 3 Spinal Muscular Atrophy (SMA) Treated with Risdiplam (RG7916) (S25.007)","author":"Mercuri E, Baranello G, Kirschner J","year":"2019","unstructured":"Mercuri E, Baranello G, Kirschner J, et al. Update from SUNFISH Part 1: Safety, Tolerability and PK\/PD from the Dose-Finding Study, Including Exploratory Efficacy Data in Patients with Type 2 or 3 Spinal Muscular Atrophy (SMA) Treated with Risdiplam (RG7916) (S25.007). Neurology. 2019: 92(15 Supplement):S25.007"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.447"},{"key":"e_1_3_4_117_1","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3389\/fneur.2019.00898","article-title":"Biomarkers and the development of a personalized medicine approach in spinal muscular atrophy","volume":"10","author":"Kariyawasam DST","year":"2019","unstructured":"Kariyawasam DST, D\u2019Silva A, Lin C, et al. Biomarkers and the development of a personalized medicine approach in spinal muscular atrophy. Front Neurol. 2019;10:898.","journal-title":"Front Neurol"},{"issue":"5","key":"e_1_3_4_118_1","doi-asserted-by":"crossref","first-page":"e020907","DOI":"10.1136\/bmjopen-2017-020907","article-title":"Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives","volume":"8","author":"Farrar MA","year":"2018","unstructured":"Farrar MA, Carey KA, Paguinto SG, et al. Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives. BMJ Open. 2018;8(5):e020907.","journal-title":"BMJ Open"},{"issue":"4","key":"e_1_3_4_119_1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40271-020-00415-w","article-title":"\u201cThe whole game is changing and you\u2019ve got hope\u201d: australian perspectives on treatment decision making in spinal muscular atrophy","volume":"13","author":"Farrar MA","year":"2020","unstructured":"Farrar MA, Carey KA, Paguinto SG, et al. \u201cThe whole game is changing and you\u2019ve got hope\u201d: australian perspectives on treatment decision making in spinal muscular atrophy. Patient. 2020;13(4):389\u2013400.","journal-title":"Patient"},{"issue":"6","key":"e_1_3_4_120_1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/dmcn.15135","article-title":"Family, healthcare professional, and societal preferences for the treatment of infantile spinal muscular atrophy: a discrete choice experiment","volume":"64","author":"Carey KA","year":"2022","unstructured":"Carey KA, Farrar MA, Kasparian NA, et al. Family, healthcare professional, and societal preferences for the treatment of infantile spinal muscular atrophy: a discrete choice experiment. Dev Med Child Neurol. 2022;64(6):753\u2013761.","journal-title":"Dev Med Child Neurol"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0918-z"},{"issue":"5","key":"e_1_3_4_122_1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.nmd.2020.02.019","article-title":"Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019","volume":"30","author":"Mercuri E","year":"2020","unstructured":"Mercuri E, Messina S, Montes J, et al. Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019. Neuromuscul Disord. 2020;30(5):431\u2013436.","journal-title":"Neuromuscul Disord"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10332-5"},{"key":"e_1_3_4_124_1","doi-asserted-by":"crossref","first-page":"100899","DOI":"10.1016\/j.spen.2021.100899","article-title":"Spinal muscular atrophy treatments, newborn screening, and the creation of a neurogenetics urgency","volume":"38","author":"Butterfield RJ","year":"2021","unstructured":"Butterfield RJ. Spinal muscular atrophy treatments, newborn screening, and the creation of a neurogenetics urgency. Semin Pediatr Neurol. 2021;38:100899.","journal-title":"Semin Pediatr Neurol"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.08.028"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.02.014"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00899-0"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2023.2218549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T17:17:16Z","timestamp":1696007836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2023.2218549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":126,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,3]]}},"alternative-id":["10.1080\/14737175.2023.2218549"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2023.2218549","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}